Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Daveson, James
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Recruiting	3	612	Europe, Canada, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
NCT05660109 / 2022-001656-41: A Study to Assess the Safety of TPM502 in Adults With Celiac Disease	Completed	2	38	Europe, RoW	TPM502, Placebo	Topas Therapeutics GmbH, Topas Therapeutics GmbH	Celiac Disease	07/24	07/24
Bali, Venita
FAME 1 EYE, NCT01320345 / ACTRN12611000249954: The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.	Recruiting	3	450	Europe, RoW	Fenofibrate, Inert lactose placebo	University of Sydney, National Health and Medical Research Council, Australia, Juvenile Diabetes Research Foundation Australia, Mylan Pharmaceuticals Inc	Type 1 Diabetes Mellitus, Diabetic Retinopathy, Diabetic Nephropathies	12/24	12/25